Hans Vitzthum has more than 25 years experience in institutional sales and healthcare research product management at Leerink Partners, Cowen & Co., and Lazard Capital Markets. Hans spent 12 years running the morning research call at two investment banks and has served as “Deal Captain” on more than 100 healthcare IPOs and secondary offerings. Hans has worked in healthcare research product management for the past 15 years and has developed extensive and long-standing relationships with the institutional investment community. Hans earned his Applied Baccalaureate from Columbia College.
Matt has 30 years experience in the healthcare arena, both as a Wall Street professional and pharmaceutical executive. Matt has extensive development-to-market experience having led the efforts to bring several important new drugs to commercialization including Synagis (MedImmune) and Cinryze (Lev Pharmaceuticals) and is a Founder of Algorithm Sciences.. He also has more than 13 years experience as a buy-side and sell-side equity research analyst and investment banker. Most recently, Matt was Managing Director at Roberts Mitani, a global, healthcare focused investment bank; where he focused on strategic transactions and financing. Additionally, he serves as a healthcare advisor to the Capital M Group, a multi-strategy investment firm. Previously, Matt co-founded Black Diamond Research, LLC where he specialized in healthcare/biotechnology research and analysis. He also serves on the Board of Directors of CorMedix, Inc., a publically traded healthcare company focused on development and launch of products in the Cardio-Renal field. Matt received his undergraduate degree from Duke University. He holds Series 7, 63 and 65 securities licenses. Matt served as the Treasurer of Ridgefield Academy an Independent School in Ridgefield, CT, and was a Member of the Board of Trustees.
Bob has over 25 years of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. He has extensive experience with health care companies, especially in the medtech, diagnostics and specialty pharma sectors. Bob focuses on providing CEOs and CFOs with strategic advice on key investor issues in order to enhance stock valuation through effective and compelling messaging and clear, consistent communications with institutional investors.Bob’s experience and perspective as an investor in public and private health care companies informs his strategic investor relations work for companies with market capitalizations from $100 million to over $50 billion. He has worked with medtech and spec pharma areas in providing ongoing investor relations advice as well as working on IPOs, follow-on offerings and equity-linked securities. In addition, Bob has advised companies in M&A transactions, dual track processes, and C-suite executive transitions. Before joining ICR, Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital, a fund with $1.5 billion of AUM, for 10 years with responsibility for all health care investing. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world’s largest private equity and venture capital firms, investing in health care. Bob was a member of the Board of Directors of The Medicines Company (MDCO) and Eurand international, which was acquired by Aptalis Pharma. He spent 15 years in investment banking, including serving as Managing Director in Health Care Finance Group at Bear Stearns & Co., having worked on capital markets and M&A transactions in excess of $5.0 billion. Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.
Chris has over 20 years of experience in the life sciences industry covering business development, investor relations, public relations, journalism, investing, and molecular neurobiology. He is the founder of BioConfidant Sàrl a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals. Previously, while at Addex Therapeutics (SIX:ADXN), Chris was a member of the executive management board and held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). He co-founded the Alpine Institute for Drug Discovery in 2013, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. In addition, Chris worked as: a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an Associate at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.
Managing Director, Israel
Moran brings over 15 years of Investor Relations experience, having worked with Israel’s largest and most prominent private and publicly traded companies. Prior to joining LifeSci Advisors, Mrs. Meir-Beres was a senior account executive at KM Investor Relations, Israel’s first and largest IR firm, where she provided companies from a wide range of sectors ongoing investor and financial media relations advice, as well as advisory services related to public and private securities offerings, mergers and acquisitions, and crisis management. Prior to joining KM, Ms Meir-Beres was part of the IR team at Teva (NYSE: TEVA), Israel’s largest healthcare company. Moran earned her BA and Master Degree in Law from Bar-Ilan University in Israel.
David Sherman has studied neuroscience for over nine years with broad exposure to translational research and cutting-edge technology. He has a deep understanding of biological systems that allows him to draw subtle distinctions between research programs and effectively evaluate market potential. David has a Bachelor of Arts degree in Biology from Harvard University, where he conducted a research project on motor control and Parkinson’s Disease for his senior thesis. He completed a Ph.D. at UCLA in the Department of Neurobiology studying the neural control of breathing.
Sam Slutsky has more than 4 years of experience in healthcare research. Prior to joining the LifeSci team, Sam conducted orthopedic research under Dr. Javad Parvizi at the Rothman Institute in Philadelphia. His work was presented at the American Association of Hip and Knee Surgeons (AAHKS) 24th annual meeting. Sam holds a Bachelor of Arts in Economics from the University of Rochester. He was a member of the school’s NCAA baseball team, where he compiled several accolades including all-conference and academic all-district.